Do you want to have a role where everything is in place and all you have to do is follow the process the same way it has always been done? No? Good, because that’s not how we work. At Zealand we create, innovate, and learn along the way. We don’t want to do things the traditional way or the way it has always been done. Unless that is the best way to go. We love to challenge status quo and push to do things better.
In this role, you will be the professional anchor and expert in your field, and you will play a key role in driving the drug substance strategy. You will be empowered to shape the direction and the role generally as well as how you execute it daily. Furthermore, you are not only empowered to, but expected to executive decision-making and take ownership of your area.

Work description:

• Primarily early phase drug substance development (tox, phase 1 & 2).
• Manage the collaboration with DS CMO (follow up on oversight plans and day-to-day communication, and securing transfer of knowledge)
• Contribute to risk assessments and CQA development at the CMO
• Review of documentation from CMO’s (batch records, risk assessments, reports etc.)
• Participation in cross functional CMC teams
• Driving scientific and strategic input to submissions/regulatory interactions in collaboration with Regulatory Affairs

Skills and experience:

• A M.Sc/PhD within chemistry, biochemistry, pharmaceutical sciences, or another relevant field.
• +3 years experience from the Pharmaceutical Industry
• Experience with solid phase peptide synthesis and input to process optimization
• Experience with outsourcing of drug substance production at CMO’s
• Experience with Quality Risk Management on DS
• Experience with regulatory aspects of CMC work and GMP
• Experience with participating in cross functional project teams and well-developed collaboration skills
• Strong oral and written communication skills in English
• Great people and stakeholder management skills
• The ability and engagement to “walk the extra mile”
• Ability to work in a dynamic environment and motivation for taking on new challenges

You will be joining a team that consists of 3 technologists, 3 analytical scientists, 2 drug product specialists, 1 CMC-PM and 1 HoD. We are not limited to our area of expertise and help where and when it is needed. We work closely together both inter and intra departmental - having the same goal and at the same time a lot of FUN. Our department goal is to help a colleague succeed – we follow that every day.

What we offer:
Our employees are fundamental to our success, and we continue to be able to attract and retain people with vast experience and talent. We have a unique culture, characterized by excellent teamwork and strong engagement across the organization.
Our work environment is charachterized by strong cross functional teamwork, room for individual performance and development, informality and respect, high work-ethics and engagement, and fun.

At Zealand, we understand the value of a diverse workforce. As an employee, you will be part of an innovative, cross-disciplinary, and cross-cultural working environment.

We offer a combined compensation package which includes a base salary, pension, bonus, and an attractive warrant program. We care about our employees’ well-being and offer health insurance, use of massage, fitness, and a range of social clubs and activities. To find out more about working at Zealand, visit our careers site and view our company video at:
www.zealandpharma.com/zealand-as-a-work-place/ & www.zealandpharma.com/video-about-zealand-new/

Application
Please apply no later than 17^th of June, 2022. Applications will be evaluated on an on-going basis.
For further information, please contact Lise Giehm at +45 5060 3692 or LGiehm@zealandpharma.com


About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Additionally, the portfolio includes clinical license collaboration with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.